SEC inhibitor KL-1 (Synonyms: KL-1) |
| カタログ番号GC38063 |
SEC 阻害剤 KL-1 (KL-1) は、ペプチド模倣リード化合物であり、強力な選択的超伸長複合体 (SEC) 阻害剤であり、SEC 足場タンパク質 AFF4 と P-TEFb の間の相互作用を妨害し、Pol II の放出障害を引き起こします。プロモーター近位の一時停止部位と、連続的な転写伸長の平均速度の低下から。 SEC 阻害剤 KL-1 は、AFF4-CCNT1 相互作用に対して用量依存的な阻害効果を示し、Ki は 3.48 μM です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 900308-84-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SEC inhibitor KL-1 (KL-1), a peptidomimetic lead compound, is a potent, selective super elongation complex (SEC) inhibitor and disrupts the interaction between the SEC scaffolding protein AFF4 and P-TEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC inhibitor KL-1 exhibits an dose-dependent inhibitory effect on AFF4-CCNT1 interaction with a Ki of 3.48 μM[1].
[1]. Liang K, et al. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced CancerTherapy. Cell. 2018 Oct 18;175(3):766-779.
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *